![BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes | Clinical Epigenetics | Full Text BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes | Clinical Epigenetics | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13148-020-00943-0/MediaObjects/13148_2020_943_Fig5_HTML.png)
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes | Clinical Epigenetics | Full Text
![IJMS | Free Full-Text | RAGE Mediates Cholesterol Efflux Impairment in Macrophages Caused by Human Advanced Glycated Albumin IJMS | Free Full-Text | RAGE Mediates Cholesterol Efflux Impairment in Macrophages Caused by Human Advanced Glycated Albumin](https://www.mdpi.com/ijms/ijms-21-07265/article_deploy/html/images/ijms-21-07265-g004b-550.jpg)
IJMS | Free Full-Text | RAGE Mediates Cholesterol Efflux Impairment in Macrophages Caused by Human Advanced Glycated Albumin
![BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes | Clinical Epigenetics | Full Text BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes | Clinical Epigenetics | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13148-020-00943-0/MediaObjects/13148_2020_943_Fig1_HTML.png)